UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 11, 2007

Access Pharmaceuticals, Inc.			
(Exact name of re			rter)
Delaware			
	n) (Commission File Number) (I.R.S. Employe Identification No.)		
2600 Stemmons Free			75207
(Address of principal executive offices) (Zip Code)			
Registrant's telephone	number, includ	ing area code:	(214) 905-5100
Item 1.01 Entry into a M	aterial Definiti	ve Agreement	

On June 11, 2007, Access Pharmaceuticals, Inc. ("Access") entered into an amendment to its 7.0% (Subject to Adjustment) Convertible Promissory Notes with Oracle Partners LP, Oracle Institutional Partners LP, SAM Oracle Investments Inc. and Oracle Offshore Ltd. agreeing to extend the maturity date of the notes to July 27, 2007 from June 12, 2007. The notes in aggregate total \$4,015,000.

On June 11, 2007, Access entered into an amendment to its 7.5% Convertible Notes with SCO Capital Partners LLC, Beach Capital LLC and Lake End Capital LLC agreeing to extend the maturity date of the notes to July 26, 2007 from June 11, 2007. The notes in aggregate total \$6,000,000.

All other terms of the notes remain the same.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By: /s/ Stephen B. Thompson

Stephen B. Thompson Vice President and Chief Financial Officer

Dated June 11, 2007

3